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Abstract
Background: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis,
which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors
(ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good
performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies
are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2,
consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).
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Methods: This investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the
hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited
metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-
metastatic: ≤5 or poly-metastatic: 6 to 10) and randomised to the experimental-arm (E-arm) or the control-arm (C-arm).
The C-arm will receive SOC, according to the local protocol. E-arm oligo-metastatic patients will receive SABR to all
lesions followed by L19-IL2 therapy; radiotherapy for poly-metastatic patients consists of irradiation of one
(symptomatic) to a maximum of 5 lesions (including ICI in both arms if this is the SOC). The accrual period will be 2.5-
years, starting after the first centre is initiated and active. Primary endpoint is PFS at 1.5-years based on blinded
radiological review, and secondary endpoints are overall survival, toxicity, quality of life and abscopal response.
Associative biomarker studies, immune monitoring, CT-based radiomics, stool collection, iRECIST and tumour growth
rate will be performed.
Discussion: The combination of SABR with or without ICI and the immunocytokine L19-IL2 will be tested as 1st, 2nd
or 3rd line treatment in stage IV NSCLC patients in 14 centres located in 6 countries. This bimodal and trimodal
treatment approach is based on the direct cytotoxic effect of radiotherapy, the tumour selective immunocytokine L19-
IL2, the abscopal effect observed distant from the irradiated metastatic site(s) and the memory effect. The first results
are expected end 2023.
Trial registration: ImmunoSABR Protocol Code: NL67629.068.18; EudraCT: 2018–002583-11; Clinicaltrials.gov: NCT03
705403; ISRCTN ID: ISRCTN49817477; Date of registration: 03-April-2019.
Keywords: Immunotherapy, L19-IL2, Anti-PD-L1, Anti-PD-1, Radiotherapy, SABR, Phase 2, NSCLC, Stage IV, Multicentre
Background
Lung cancer is the leading cause of cancer-related death
worldwide [1, 2], with an estimated mortality of 3.1 mil-
lion in 2040 [3]. Non-small cell lung cancer (NSCLC) is
the most common lung cancer type (85% of cases) and
half of these patients have metastatic disease at initial
diagnosis [4]. Immune checkpoint inhibitors (ICI), either
alone for selected patients (Programmed Cell Death-
ligand 1 (PD-L1) ≥ 50% EU and PD-L1 ≥ 1% in USA), or
in combination with chemotherapy, have become the
standard of care (SOC) for most good performance sta-
tus (PS) patients with metastatic disease [5]. Metasta-
sized NSCLC patients with oligo-metastatic disease
showed a benefit in progression free survival (PFS) when
local ablative therapy was added to systemic therapy
(chemotherapy ([6–8]) or tyrosine kinase inhibitor ([7,
8])); one trial also demonstrated an improved overall
survival (OS) [7]. Oligometastatic disease is usually de-
fined as “limited metastasis” (NCCN guideline [9]), up to
three metastases (ESMO guideline [5]) or up to five me-
tastases (European Organization for the Research and
Treatment of Cancer (EORTC) lung cancer group con-
sensus definition [10–12] and most clinical trials [13–
15]). These guidelines advise to treat these patients with
a combination of systemic therapy and local ablative
therapy, preferably within a clinical trial.
However, most patients with oligo-metastatic disease
will not obtain long-term benefit due to resistance
mechanisms. Several immunotherapy-based treatments
have been developed to overcome this resistance and in-
crease the long-term benefit. Most immunotherapies act
on escape mechanisms like impaired antigen presenta-
tion, a decreased neoantigen repertoire and T-cell func-
tion, insensitivity to immune effector molecules, the
tumour microenvironment and co-opting of alternative
immune checkpoints [16]. In context of double ICI
treatments, so far, the results in NSCLC are disappoint-
ing. The randomized phase III Checkmate 227
(NCT02477826) trial (nivolumab-ipilimumab) demon-
strated prolonged 2-year OS compared to chemotherapy
alone, independent of PD-L1 expression [17], albeit with
a comparator arm (platinum doublet chemotherapy)
which is now considered inferior [18]. On the other
hand, the phase III MYSTIC (NCT02453282) and NEP-
TUNE (NCT02542293) trials (both durvalumab-
tremelimumab) were reported negative for their primary
endpoints [19, 20]. One option to improve OS is the
addition of radiotherapy to ICI, as radiation might act
synergistically with ICI on the immune system [21–23].
The added value of ICI has already been shown in stage
III NSCLC, in which adjuvant durvalumab after concur-
rent chemoradiotherapy in patients with good PS re-
sulted in an improved median PFS and OS, as well as an
improved 3-year survival (66.3% versus 43.5%) [24, 25].
In stage IV NSCLC, early signals of efficacy have been
observed. Albeit negative in the intention to treat popu-
lation, the PEMBRO-RT phase II trial (NCT02492568)
showed that combining pembrolizumab with stereotactic
ablative radiotherapy (SABR) significantly increased the
OS (12 months: 55% vs 36%, 18 months: 48% vs 28%) of
PD-L1-negative NSCLC patients without increasing tox-
icity compared to pembrolizumab alone [26].
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As the combination of radiotherapy and ICI still does
not result in long-term benefit for most patients, the
addition of new immunotherapy modalities to radiation
should be explored. Based on personal communication,
we know that L19-interleukin 2 (IL2) (darleukin; 15
MIO IU) has shown promising results in a phase I trial
(NCT02086721) when combined with SABR in oligo-
metastatic cancer patients. Two NSCLC patients (33%)
are still without progression, respectively 3 and 4 years
after treatment completion. Importantly, the combin-
ation did not result in grade 3 or higher toxicity. Based
on these promising phase I data, we are performing a
randomised phase II trial.
Rationale
IL2 is a cytokine that plays an essential role in the acti-
vation of the innate and specific immune response [27,
28]. Unfortunately, the use of systemic administered IL2
is limited due to its serious acute toxicity profile which
require intensive inpatient management [29]. Neverthe-
less, coupling IL2 to a tumour specific antibody, like
L19, reduces the IL2 concentration in blood and in-
creases the concentration in the tumour [30, 31], result-
ing in only low grade toxicity [32]. L19-IL2 is a fully
human immunocytokine consisting of the human cyto-
kine IL2 fused to the single-chain (scFv) human antibody
fragment L19 targeting extra-domain B (ED-B) explicitly
[33]. ED-B of fibronectin (FN) is a type III-FN domain,
which can be inserted in the protein molecule by a
mechanism of alternative splicing [34]. ED-Bcontaining
fibronectin is a well-characterised marker of neo-
angiogenesis and is expressed in the extracellular matrix
surrounding newly formed blood vessels. As such, it is
abundantly expressed around the vasculature of a variety
of human cancers [35–37], while it is usually not present
in healthy adult human tissues. It is known that in
NSCLC, ED-B is expressed in the vast majority (~ 82%)
of tumours [31, 38]. Darleukin represents a targeted
form of IL2, capable of selective accumulation at the
tumour site [39]. As such, this drug has the potential to
boost selective anti-tumoural immune responses in pa-
tients with NSCLC. We have demonstrated in pre-
clinical studies that L19-IL2, especially in combination
with radiotherapy, results in improved disease control in
lung and colorectal carcinoma models [21, 23]. Thera-
peutic responses were dependent on the irradiation dose,
the target expression levels and are causally related to
the presence of CD8+ cytotoxic T cells [21]. Best re-
sponses were found when administrating L19-IL2 after
radiotherapy [40, 41]. Additionally, we have shown that
this combination leads to improved local tumour control
as well as tumour regression outside of the radiotherapy
field and induces an immune-mediated memory effect
preventing tumour-relapse after reinjection of tumour
cells [23]. Furthermore, in pre-clinical Lewis Lung Car-
cinoma (LLC) models, we have observed that the syn-
ergy of radiotherapy with L19-IL2 is superior to the
combination of radiotherapy with ICI. Interestingly,
combining RT, L19-IL2 and ICI resulted in curative re-
sponses for this low immunogenic tumour model, which
were associated with increased infiltration of NK and
CD8+ T cells without any signs of toxicity [42]. Several
trials with stage IV malignancies found 22.5 Mio IU as
recommended L19-IL2 dose as monotherapy [32, 43, 44]
or combined with dacarbazine [43, 44]. We recently re-
ceived, based on personal communication, the safety re-
sults of L19-IL2 in the phase I trial (NCT02086721)
given 15 Mio IU after SABR, as the combination of 22.5
Mio IU L19-IL2 with SABR resulted in more grade 3
toxicity. Therefore, the 15 Mio IU will be used in the
current phase II trial protocol: ImmunoSABR
(NCT03705403), designed to test the activity and effi-
cacy of L19-IL2 (+ ICI treatment if SOC) following
SABR in oligo-metastatic and conventional radiotherapy
in poly-metastatic (maximum 10 metastatic sites) in
NSCLC patients. A maximum of 10 lesions was defined,
as patients without widespread metastases have low or
acceptable toxicity when irradiating maximum 5 out of
10 lesions, and still have an active immune system to
gain the best response on L19-IL2.
Methods/design
ImmunoSABR is a multicentre, randomised controlled
open-label phase II clinical trial testing the hypothesis
that the combination of (SAB)R and the immunocyto-
kine L19-IL2 will increase the PFS in patients with lim-
ited metastatic NSCLC compared to SOC (including ICI
in both arms if this is the SOC). After randomisation by
minimisation, patients will be assigned either to the ex-
perimental arm (E-arm) or the control arm (C-arm) as
described in Fig. 1.
Study population
The trial will consist of one cohort of 126 adult patients
with stage IV NSCLC. ImmunoSABR will act as 1st, 2nd or
maximum 3rd line treatment, and will be different for pa-
tients with oligo-metastatic NSCLC (max 5 metastases
[11]) and patients with poly-metastatic NSCLC (6–10 me-
tastases). As SOC and OS differ between oligo-metastatic
and poly-metastatic patients [7], oligo versus poly will be
used as a stratification factor for randomisation. Also, ICI
maintenance treatment, centre, histology (squamous versus
non-squamous), gender and driver mutation (equally divide
previously TKI treated patients with oncogenic drivers) will
be added as stratification factors. Patients will be rando-
mised into 2 arms, using randomisation by minimisation
(ALEA software): E-arm or C-arm. The algorithm uses a
random factor to prevent the possibility of upfront
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knowledge about the randomisation result. All data col-
lected for this trial will be entered in and stored on an on-
line clinical data management platform containing pre-
structured electronic case report forms per patient visit.
Sample size calculation
The expected 1.5-year PFS is minimally 15% in the C-arm
and at least 35% in the E-arm. A sample size of 116 pa-
tients (58 patients per treatment arm) is needed to show
this difference (20%) in PFS, using a Log-Rank test with a
two-sided alpha of 0.05 and power of 85%. Patients will be
evenly divided over the two arms during an accrual period
of 2.5 years. Assuming a drop-out rate of 10%, a total of
126 patients (63 per arm) need to be included.
Study treatment
A complete overview of the inclusion and exclusion cri-
teria is described in supplementary Table 1. Main inclu-
sion criteria are NSCLC, ≤10 metastatic lesions at
baseline, world health organization preformance status
(WHO PS) 0–1 and adequate bone marrow, liver and
renal function. Most important exclusion criteria are a
systemic infection, pregnancy, history of organ transplant,
autoimmune disease and impaired/uncontrolled cardio-
vascular function. All potentially eligible patients have to
sign the informed consent (ICF) (see supplementary Table
2 for the ICF) and will subsequently be examined with re-
spect to medical history, physical examination, WHO PS,
vital signs, height and body weight, general and viral blood
tests (e.g. Creatinine, total protein, albumin, ALAT,
ASAT, alkalic phosphatase, γ-GT, bilirubin, Hb, WBC and
differentiation, platelets, PT and aPTT, HIV, HBV and
HCV) and a pregnancy test in women of child-bearing po-
tential. The participants fulfilling the afore-mentioned cri-
teria will undergo baseline imaging (e.g. fluordeoxyglucose
Positron Emission Tomography/Computed Tomography
(FDG PET/CT) and brain Magnetic Resonance Imaging
(MRI)) as performed in respective institutes before being
randomised (t = 0) into the C-arm or E-arm, see Figs. 1
and 2.
Fig. 1 Study design of ImmunoSABR phase II trial
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The participants fulfilling the eligibility criteria will
undergo a SOC baseline imaging, translational
blood sampling, and other baseline requirements
before being randomised (t=0) into the C-arm or E-
arm. Shortly after randomisation, the first fraction
of (SAB)R will be planned. L19-IL2 will start within
72 hours after last fraction. Every patient will re-
ceive 6 cycles, which consist each of 21 days. Simul-
taneously with these cycles, ICI will be administered
if SOC. Follow-up for a period of 1.5 years after
randomisation.
The SOC protocol will be applied for the patients
within the C-arm, while having the same time points as
the E-arm for translational samples and follow-up. Pa-
tients are allowed to have had front-line systemic ther-
apy and/or treatment to the primary tumour prior to the
trial, however, this is not obligatory. The participants in
the E-arm will start with (SAB)R to maximum 5 meta-
static lesions, according to a dose-fractionation regimen
chosen by the research physician’s discretion. However,
some study guidelines need to be taken into account: the
minimum dose per fraction to the metastasis should be
7Gy for oligo-metastatic and 4Gy for poly-metastatic
disease, with a relative biological effectiveness of in total
30-60Gy for oligo-metastatic and 8-35Gy for poly-
metastatic disease, within every day or every second day
between fractions [45–49]. The dose constraints for vari-
ous critical organs suggested by the AAPM task group
101 should be respected [50]. To decrease the risk of
radiation-induced lymphopenia, irradiation of large ves-
sels (e.g. aorta), spleen and the heart should be avoided
whenever possible [51]. Furthermore, irradiation sched-
uling should be organised to allow the first administra-
tion of L19-IL2 within 72 h after the last irradiation for
patients randomised to the E-arm.
The participants in the E-arm will receive 6 cycles of
L19-IL2 (and ICI maintenance treatment before every
first L19-IL2 infusion of every cycle if SOC). Figure 2
and the supplementary Table 3 show a detailed timeline
overview. One cycle L19-IL2 consists of three adminis-
trations of L19-IL2 at days 1, 3 and 5. Cycles are re-
peated every 3 weeks. At day 3 of each cycle, the quality
of life (QoL) questionnaires EQ-5D, QLQ-C30 v3.0 and
QLQ-LC13 will be filled out. Furthermore, before every
L19-IL2 infusion, multiple tests will be performed, e.g.
recording concurrent medication, blood tests, blood
pressure, temperature, heart rate, WHO PS (0–1) and
scoring adverse events with CTCAE v5.
During the first 3 h L19-IL2 infusion cycle, blood pres-
sure, temperature and heart rate are assessed every 30
min, at the end of the administration and subsequently
after 30 min, 1 h and 2 h following the administration. If
no significant changes are seen in blood pressure,
temperature and heart rate during the first 2 cycles, only
end of infusion assessment will be required for subse-
quent cycles.
Follow-up
In each centre, both arms will receive follow-up on the
same time points, based on their SOC (every 6 weeks
versus every 12 weeks). For both arms, there will be
follow-up CT-scan(s) with IV contrast (slice thickness of
≤ 3 mm), WHO PS and Quality of Life questionnaires to
be completed at least every 12 weeks. Also, translational
blood samples are taken simultaneously with the
planned CT-scans in week 12, 24 and 36. Blinded local
radiological review will be performed for every follow-up
scan to assess tumour response using RECIST (version
1.1, [52]) and exploratory iRECIST [53].
Response criteria are based on a set of measurable le-
sions identified at baseline as target lesions for RECIST
evaluation, and followed until disease progression. If all
lesions are irradiated, RECIST is less accurate. In case of
doubt, we propose a panel discussion. Follow-up and
treatment for patients progressing will be done
Fig. 2 Timeline of study treatment and follow-up
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according to the local standard protocols. Patients will
be followed every 3 months to record OS, toxicity, QoL
and adverse events for 1.5 years. The PFS and OS will be
collected for a total of 5 years.
Study parameters and endpoints
The main objective of the trial is to test if the combin-
ation of (SAB)R and the immunocytokine L19-IL2 (and
ICI in case of SOC) will result in an increased PFS rate
at 1.5 year after randomisation compared to the SOC,
based on blinded radiological review (RECIST 1.1). The
secondary objectives will be an assessment of 5-years
PFS, 1.5-year and 5-year OS and 1.5-year CTCAE v5
toxicity grade, QoL, Out of Field Radio-Immune re-
sponse (target(s) for RECIST analysis 1.1) and In-Field
Radio-Immune response (non-target(s) for RECIST ana-
lysis). Exploratory analyses will be performed to investi-
gate biomarkers (e.g. ED-B expression on tumour
biopsies), diversity of the microbiota of faeces, CT radio-
mics and the changes of immunologic markers in re-
peated peripheral blood samples. The statistical methods
are described in supplementary Table 4.
Nature and extent of the burden and risks associated
with participation, benefit and group relatedness
ICI, either alone for selected patients or in combination
with chemotherapy, have become the SOC for most
good PS patients with metastatic disease [5]. A specific
population of metastasized NSCLC patients, namely
those with oligo-metastatic disease, can obtain long-
term survival with the addition of local ablative therapy
[6, 7]. However, most patients (oligo- and poly-
metastatic) do not obtain long-term survival and new
treatment strategies are therefore needed. The ultimate
aim of the combination of (SAB)R and L19-IL2 (with
ICI if SOC) is to prolong PFS by inducing an immune
response which would be able to control this systemic
disease. Known/potential risks additional to the SOC
treatment include:
L19-IL2 related side effects
Fever with chills, fatigue, nausea, vomiting, asthenia,
(peripheral) oedema, skin rash, hyperhidrosis, chest
pain, pruritus, elevated serum creatinine levels and
pain at the tumour site. Signs of mild capillary leak
syndrome and hypotension were found at the dose-
limiting dosage level that is not administered in the
current trial [32, 43, 54–58]. Most of the severe ad-
verse events were seen in studies using a higher dose
of L19-IL2 (22.5–30 Mio IU) compared to our phase
I study dose of 15 Mio IU where no grade 3 or more
toxicities occurred. We therefore expect, based on our
experiences in the phase I trial, that the incidence
and intensity of the adverse events are lower in the
current phase II trial. Experiences from our phase 1
trial combined with published IL2-management guide-
lines [59–61] will be used as guidance when side ef-
fects occur.
(SAB)R related side effects
(SAB)R side effects are dependent on the location of the
irradiated site. Toxicity is considered very low and the
risk of radiation-induced lymphopenia will be decreased
by avoiding, whenever conceivable, the irradiation of
large vessels (e.g. aorta), spleen and the heart. Possible
side effects are nausea, vomiting, diarrhoea for abdom-
inal sites, local pain, discomfort and neuritis for soft tis-
sue and bony sites and dyspnoea, cough, radiation
pneumonitis and rib fractures for thoracic sites. Studies
evaluating SABR to mixed oligo-metastatic sites report
grade III toxicity rates below 12%, like bowel strictures,
fatigue, dyspnoea, pain but also treatment-related death
(e.g. radiation pneumonitis, pulmonary abscess) [62].
There might be an increased risk of immune-related tox-
icity for those patients receiving L19-IL2 and radiother-
apy in combination with standard treatment
pembrolizumab. Immune-related toxicity from standard
of care pembrolizumab is rare, but can be serious and
life-threatening [63]. Knowing that metastatic NSCLC is
a mortal disease in the short-term, the potential burden
seems proportional to the potential gain.
An independent Data Safety Monitoring Board
(DSMB) has been established and will monitor patient
recruitment, adverse effects reporting and data quality
during the trial. A first safety analysis is planned after
the first 15 patients treated with triple therapy. All Ser-
ious Adverse Events and Suspected Unexpected Serious
Adverse Reactions (SUSAR) will be reported to the
manufacture and following country specific and Euro-
pean Medicine Agency (EMA) guidelines.
Translational research
The translational research will focus on immunological
marker evaluation oriented towards both finding prognos-
tic and predictive biomarkers that will indicate sensitivity
to (SAB)R/L19-IL2 treatment. Also, blood (e.g. neutrophil
counts [64], lymphocyte counts [65–67], LIPI score [68],
circulating tumour DNA [69], cell-free tumour DNA [70]
and immune cell subsets), tissue (e.g. ED-B expression,
somatic mutations [71], non-synonymous mutation load
[72, 73], PD(L)-1 expression, neutrophil and macrophage
type 2 levels, Immune cell subsets) and faeces (diver-
sity in microbiota) markers related to the importance
of immunological checkpoints for the L19-IL2 inter-
action will be assessed. The samples will be collected
(only in case of patient informed consent) and stored
for 15 years, supplementary Table 5.
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Radiomics is one of the most promising techniques
that have the potential to improve cancer prognosti-
cation [65, 67]. In Radiomics, large numbers (1500+)
of quantitative features such as tumour image inten-
sity, (multi-scale) texture and the shape and size of a
tumour are extracted from standard medical images
(CT, PET, MRI) using (semi)automatic software.
Radiomics enables identification of quantitative im-
aging biomarkers (QIBs) to quantify and classify
tumour phenotypes and other disease parameters
non-invasively. An exploratory correlative analysis
will be conducted on the available PET-CT / diag-
nostic and simulation CT / MRI data obtained prior
and during this trial. All the scans will be de-
identified and collected every year and at the end of
the trial [74]. We have three main hypotheses: (A)
Studies suggest that the mutational landscape in tu-
mours influences the response to immunotherapy, as
higher non-synonymous mutation burden in tumours
was associated with an improved objective response,
durable clinical benefit and PFS [46, 47]. However,
analysing these mutations in tissues is currently a
complex and laborious process. We hypothesise that
these phenotypic differences in a tumour can be
characterised non-invasively by applying radiomics;
the heterogeneous tumours will be more sensitive to
immunotherapy than less heterogeneous tumours.
(B) Hypoxia immunological niche: Hypoxia is a
negative prognostic factor possibly causing resistance
to immunotherapy [75]. We hypothesise that radio-
mics can be applied to assess tumour hypoxia and
thus can be used as a predictive factor for treatment
response. (C) We hypothesise that radiomics can
more accurately assess the progression of the disease
than RECIST.
The tumour growth rate (TGR) before and during
treatment and variation per period will give insights in
tumour development but also more information regard-
ing treatment specific response. All available scans prior
to (incl diagnostic scan) and during this trial will be used
to visualise the TGR and determine hyperprogressive
disease, based on [76].
Discussion
A recent phase I study revealed the safety of the bimodal
treatment but also indicated favorable treatment re-
sponse in 2/6 patients being still progression-free for re-
spectively 3 and 4 years. ImmunoSABR, a randomised
phase II study, is the first randomised, investigator-
initiated and intention to treat clinical trial that gener-
ates a reliable evidence base to change clinical practice
from palliative to a curative treatment strategy in pa-
tients with limited metastatic NSCLC.
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